BACKGROUND AND AIMS: The expression patterns of cyclins D1 and E as well as cyclin-dependent kinase inhibitors p21/waf1 and p27/kip1 and their correlation with clinical parameters and other cell cycle regulators was investigated in inflammatory bowel disease (IBD). PATIENTS AND METHODS: These molecular markers were localized immunohistochemically using the monoclonal antibodies anti-cyclin D1 (DCS-6), anti-cyclin E (13A3), anti-p21 (4D10) and anti-p27 (1B4) in 70 patients with IBD, 30 patients with colorectal cancer and eight healthy subjects. Data were analyzed statistically using the software program. RESULTS: Cyclin D1 expression was higher in both UC and CD compared with the healthy control group. In addition, CD cyclin D1 expression was higher compared with UC cases and colorectal carcinomas. Cyclin D1 expression was correlated with disease activity and cell proliferation in UC cases. A positive relationship of cyclin D1 with p27/kip1 in both UC and CD was detected. Cyclin E expression was higher in UC, CD and carcinomas compared with healthy control group and its expression correlated with proliferative activity in both UC and CD cases. p21/waf1 expression was higher in IBD cases compared with that of the control group, while a decreased p21/waf1 expression in the group of carcinomas was noted. This expression was correlated with disease activity in UC and the proliferative activity in both UC and CD. The expression of cyclins D1 and E as well as p21/waf1 was also correlated with the existence of dysplastic lesions. A lower p27/kip1 expression in the group of carcinomas compared with IBD cases and healthy controls was found. CONCLUSIONS: The expression patterns of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in IBD may indicate their contribution in epithelial cell turnover and their possible implication in IBD-related dysplasia-carcinoma.
BACKGROUND AND AIMS: The expression patterns of cyclins D1 and E as well as cyclin-dependent kinase inhibitors p21/waf1 and p27/kip1 and their correlation with clinical parameters and other cell cycle regulators was investigated in inflammatory bowel disease (IBD). PATIENTS AND METHODS: These molecular markers were localized immunohistochemically using the monoclonal antibodies anti-cyclin D1 (DCS-6), anti-cyclin E (13A3), anti-p21 (4D10) and anti-p27 (1B4) in 70 patients with IBD, 30 patients with colorectal cancer and eight healthy subjects. Data were analyzed statistically using the software program. RESULTS:Cyclin D1 expression was higher in both UC and CD compared with the healthy control group. In addition, CDcyclin D1 expression was higher compared with UC cases and colorectal carcinomas. Cyclin D1 expression was correlated with disease activity and cell proliferation in UC cases. A positive relationship of cyclin D1 with p27/kip1 in both UC and CD was detected. Cyclin E expression was higher in UC, CD and carcinomas compared with healthy control group and its expression correlated with proliferative activity in both UC and CD cases. p21/waf1 expression was higher in IBD cases compared with that of the control group, while a decreased p21/waf1 expression in the group of carcinomas was noted. This expression was correlated with disease activity in UC and the proliferative activity in both UC and CD. The expression of cyclins D1 and E as well as p21/waf1 was also correlated with the existence of dysplastic lesions. A lower p27/kip1 expression in the group of carcinomas compared with IBD cases and healthy controls was found. CONCLUSIONS: The expression patterns of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in IBD may indicate their contribution in epithelial cell turnover and their possible implication in IBD-related dysplasia-carcinoma.
Authors: S Girlando; P Slomp; O Caffo; M Amichetti; R Togni; G Dvornik; L Tomio; E Galligioni; P Dalla Palma; M Barbareschi Journal: Virchows Arch Date: 1999-12 Impact factor: 4.064
Authors: N Arber; H Hibshoosh; W Yasui; A I Neugut; A Hibshoosh; Y Yao; A Sgambato; H Yamamoto; I Shapira; D Rosenman; I Fabian; I B Weinstein; E Tahara; P R Holt Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-12 Impact factor: 4.254
Authors: H Uesugi; H Mitomi; M Sada; H Takahashi; K Kobayashi; M Igarashi; T Katsumata; A Ihara; Y Ohtani; S Ikeda; I Okayasu Journal: Scand J Gastroenterol Date: 1999-11 Impact factor: 2.423
Authors: N Arber; H Hibshoosh; S F Moss; T Sutter; Y Zhang; M Begg; S Wang; I B Weinstein; P R Holt Journal: Gastroenterology Date: 1996-03 Impact factor: 22.682
Authors: Mònica Comalada; Elvira Bailón; Oscar de Haro; Federico Lara-Villoslada; Jordi Xaus; Antonio Zarzuelo; Julio Gálvez Journal: J Cancer Res Clin Oncol Date: 2006-05-17 Impact factor: 4.553
Authors: Amr M Mohamed; Bassem A Refaat; Adel G El-Shemi; Osama A Kensara; Jawwad Ahmad; Shakir Idris Journal: Am J Transl Res Date: 2017-02-15 Impact factor: 4.060
Authors: Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Matthew Fosbrink; Vingh Nguyen; Philippe Azimzadeh; Violeta Rus; Hegang Chen; Petru A Mircea; Abulkalam Shamsuddin; Horea Rus Journal: Exp Mol Pathol Date: 2009-10-31 Impact factor: 3.362
Authors: Martin Floer; David G Binion; Victoria M Nelson; Sharon Manley; Michael Wellner; Saba Sadeghi; Behnaz Behmaram; Chloe Sewell; Mary F Otterson; Torsten Kucharzik; Parvaneh Rafiee Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-07-17 Impact factor: 4.052